This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin’s therapeutic effects on OCD.
The treatment protocol for this study can be found here.
Compound Psilocybin
Country United States of America
Visit trial
Trial Details
Trial Number
Sponsors & Collaborators
Yale UniversityThe Yale Psychedelic Science Group was established in 2016.
Measures Used
Yale-Brown Obsessive Compulsive ScaleThe Yale Brown Obsessive-Compulsive Scale (Y-BOSC) is considered the gold-standard to assess OCD severity. The scale consists of ten items and measures the severity and type of symptoms in people with OCD over the previous seven days. The scale is used at initial diagnosis as well as during follow up sessions after treatment. The scores range from 0 to 4, with higher scores indicating greater symptoms of OCD severity.